EAM
DNLI icon

Eventide Asset Management’s Denali Therapeutics DNLI Stock Holding History

Eventide Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-621,850
Closed -$12.8M – 159
2023
Q3 		$12.8M Buy
621,850
+308,443
+98% +$7.82M 0.23% 112
2023
Q2 		$9.25M Hold
313,407
– – 0.16% 121
2023
Q1 		$7.22M Buy
+313,407
New +$8.63M 0.13% 122

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eventide Asset Management's DNLI Position: Q4 2023 in Review

Eventide Asset Management sold out of Denali Therapeutics (DNLI) in Q4 2023, closing a stake of 621,850 shares — an estimated $12.8M sold.

Eventide Asset Management first reported a position in DNLI in Q1 2023 and held it in 3 quarters. The position peaked at $12.8M in Q3 2023. 209 funds tracked by Wall St. Rank hold DNLI as of Q4 2023.

  • Eventide Asset Management reported no remaining Denali Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Eventide Asset Management sold 621,850 Denali Therapeutics shares in Q4 2023, an estimated $12.8M.
  • Eventide Asset Management first reported a position in Denali Therapeutics in Q1 2023 and held it in 3 quarters.
  • Eventide Asset Management's Denali Therapeutics position peaked at $12.8M in Q3 2023.
  • 209 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2023.

Based on Eventide Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.